市場調査レポート
商品コード
1441931

新規インスリン製剤および送達技術の世界市場:シリンジおよびバイアルへの焦点

Global Markets for Emerging Insulin Drug and Delivery Technologies: Focus on Syringes and Vials

出版日: | 発行: BCC Research | ページ情報: 英文 158 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
新規インスリン製剤および送達技術の世界市場:シリンジおよびバイアルへの焦点
出版日: 2024年02月27日
発行: BCC Research
ページ情報: 英文 158 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の新規インスリン製剤および送達技術の市場規模は、2023年の558億米ドルから成、予測期間中は9.8%のCAGRで推移し、2028年末には889億米ドルの規模に成長すると予測されています。

インスリンシリンジおよびバイアルの市場は2023年の243億米ドルから、同期間中に8.7%のCAGRで推移し、2028年末には370億米ドルの規模に成長すると予測されています。また、スマートインスリンペンの市場規模は2023年の42億米ドルから、12.6%のCAGRで推移し、2028年末には77億米ドルの規模に成長すると予測されています。

当レポートでは、世界の新規インスリン製剤および送達技術の市場を調査し、市場および疾患の背景、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、技術・特許の動向、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 サマリー・ハイライト

  • 市場の見通し
  • 市場概要
  • 開発と動向

第3章 市場概要

  • 糖尿病とは
  • 糖尿病の種類
  • 1型糖尿病
  • 2型糖尿病
  • 妊娠糖尿病または妊娠中の高血糖
  • 耐糖能障害と空腹時血糖障害
  • 糖尿病の疫学
  • 性別分布
  • 地域格差
  • 市場力学のスナップショット
  • 市場に影響を与える要因
  • 市場促進要因
  • 市場抑制要因

第4章 世界の新規インスリン製剤および送達技術市場:タイプ別

  • 概要
  • インスリンシリンジの技術的進歩
  • インスリン送達ペン型デバイス
  • 使い捨てインスリンペン
  • 再利用可能インスリンペン
  • インスリン製剤および送達ペン型デバイスの技術的進歩
  • 外部インスリンポンプ
  • インスリンポンプシステムの技術的進歩
  • 埋め込み型インスリンポンプ
  • クローズドループ人工膵臓
  • バイオニック膵臓
  • スマートペン

第5章 世界の新規インスリン製剤および送達デバイス市場:用途別

  • 概要
  • 1型糖尿病
  • 2型糖尿病
  • 妊娠糖尿病

第6章 世界のインスリン製剤および送達デバイス市場:地域別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第7章 規制状況

  • 概要
  • 米国
  • 欧州
  • 日本
  • 中国

第8章 インスリン製剤およびデリバリー市場の持続可能性:ESGの観点

  • ESGパフォーマンス分析

第9章 新興技術

  • 血糖制御を超えた患者の転帰

第10章 特許分析

第11章 M&Aとベンチャー資金調達の見通し

  • M&A分析

第12章 競合情勢

  • 概要

第13章 企業プロファイル

  • ASTRAZENECA
  • B. BRAUN SE
  • BD
  • CARDINAL HEALTH
  • DEBIOTECH SA
  • DIABELOOP SA
  • EMPERRA GMBH E-HEALTH TECHNOLOGIES
  • EMBECTA CORP.
  • F. HOFFMANN-LA ROCHE LTD.
  • INSULET CORP.
  • JOHNSON & JOHNSON SERVICES INC.
  • LIFESCAN IP HOLDINGS LLC.
  • LILLY
  • MEDTRONIC
  • NOVO NORDISK A/S
  • NUGEN MEDICAL DEVICES
  • OWEN MUMFORD LTD.
  • SANOFI
  • SOOIL DEVELOPMENTS CO. LTD.
  • TANDEM DIABETES CARE INC.
  • TERUMO CORP.
  • YPSOMED AG

第14章 付録

図表

List of Tables

  • Summary Table : Global Market for Emerging Insulin Drug Delivery Devices, by Type, Through 2028
  • Table 1 : Latest Data for Diabetes Globally, 2021 and 2045
  • Table 2 : Global Estimates and Projections for Diabetes, 2019-2045
  • Table 3 : Diabetes Cases, by Country, 2000-2045
  • Table 4 : Age-Adjusted Comparative Prevalence of Diabetes, by Region, 2010-2045
  • Table 5 : First-Time Generic Drug Approvals for Type 2 Diabetes, July 2022 to August 2022
  • Table 6 : Global Market for Insulin Syringes and Vials, Through 2028
  • Table 7 : Global Market for Insulin Syringes, by Type, Through 2028
  • Table 8 : Leading Manufacturers of Insulin Syringes and Insulin Syringe Products, 2022
  • Table 9 : Commercially Available Insulin Injector Pens
  • Table 10 : Leading Manufacturers of External Insulin PumpsLeading Manufacturers of External Insulin Pumps
  • Table 11 : Features of Current Leading Insulin Pump Systems
  • Table 12 : Global Market for Emerging Insulin Drug Delivery Devices, by Type, Through 2028
  • Table 13 : Global Market for Emerging Insulin Drug Delivery Devices, by Region, Through 2028
  • Table 14 : Global Market for Insulin Syringes and Vials, by Region, Through 2028
  • Table 15 : Global Market for Insulin Pens, by Region, Through 2028
  • Table 16 : Global Market for Insulin Pumps, by Region, Through 2028
  • Table 17 : Global Market for Smart Pens, by Region, Through 2028
  • Table 18 : Global Market for Insulin Vials, by Region, Through 2028
  • Table 19 : Global Market for Insulin Syringes, by Region, Through 2028
  • Table 20 : Global Market for U-100 Insulin Syringes, by Region, Through 2028
  • Table 21 : Global Market for U-40 Insulin Syringes, by Region, Through 2028
  • Table 22 : Global Market for Emerging Insulin Drug Delivery Devices, by Application, Through 2028
  • Table 23 : Global Market for Type 1 Diabetes, by Region, Through 2028
  • Table 24 : Global Market for Type 2 Diabetes, by Region, Through 2028
  • Table 25 : Global Market for Gestational Diabetes, by Region, Through 2028
  • Table 26 : Global Market for Emerging Insulin Drug Delivery Devices, by Region, Through 2028
  • Table 27 : North American Market for Insulin Drug Delivery Devices, by Country, Through 2028
  • Table 28 : North American Market for Insulin Drug Delivery Devices, by Type, Through 2028
  • Table 29 : North American Market for Insulin Syringes and Vials, by Segment, Through 2028
  • Table 30 : North American Market for Insulin Syringes, by Type, Through 2028
  • Table 31 : North American Market for Insulin Drug Delivery Devices, by Application, Through 2028
  • Table 32 : European Market for Insulin Drug Delivery Devices, by Country, Through 2028
  • Table 33 : European Market for Insulin Drug Delivery Devices, by Type, Through 2028
  • Table 34 : European Market for Insulin Syringes and Vials, by Segment, Through 2028
  • Table 35 : European Market for Insulin Syringes, by Type, Through 2028
  • Table 36 : European Market for Insulin Drug Delivery Devices, by Application, Through 2028
  • Table 37 : Asia-Pacific Market for Insulin Drug Delivery Devices, by Country, Through 2028
  • Table 38 : Asia-Pacific Market for Insulin Drug Delivery Devices, by Type, Through 2028
  • Table 39 : Asia-Pacific Market for Insulin Syringes and Vials, by Segment, Through 2028
  • Table 40 : Asia-Pacific Market for Insulin Syringes, by Type, Through 2028
  • Table 41 : Asia-Pacific Market for Insulin Drug Delivery Devices, by Application, Through 2028
  • Table 42 : RoW Market for Insulin Drug Delivery Devices, by Sub-region, Through 2028
  • Table 43 : RoW Market for Insulin Drug Delivery Devices, by Type, Through 2028
  • Table 44 : RoW Market for Insulin Syringes and Vials, by Segment, Through 2028
  • Table 45 : RoW Market for Insulin Syringes, by Type, Through 2028
  • Table 46 : RoW Market for Insulin Drug Delivery Devices, by Application, Through 2028
  • Table 47 : ESG Performance Analysis of the Market for Insulin Drug and Delivery Technologies
  • Table 48 : Social Performance of the Market for Insulin Drug and Delivery Technologies
  • Table 49 : Governance Performance of the Market for Insulin Drug and Delivery Technologies
  • Table 50 : Clinical Trials Involving Insulin Drug and Delivery Technologies
  • Table 51 : Clinical Trials Involving Artificial Pancreas, as of December 2023
  • Table 52 : Approved Active Patents for Insulin Drug Delivery Devices, 2021-2023
  • Table 53 : M&A in the Global Market for Insulin Drug Delivery Devices, 2021 to June 2023
  • Table 54 : Recent Venture Funding for Insulin Drug Delivery Devices and Related Offerings
  • Table 55 : Number of Deals for Insulin Drug and Delivery Technologies, by Status, January 2018 to September 2023
  • Table 56 : Leading Manufacturers and Suppliers of Insulin Syringes and Vials
  • Table 57 : Ranking of Insulin Syringe Manufacturers, by Market Share, 2022
  • Table 58 : Ranking of Insulin Vial Manufacturers, by Market Share, 2022
  • Table 59 : Global Market Ranking for Insulin Drug Delivery Devices, 2022
  • Table 60 : AstraZeneca: Company Snapshot
  • Table 61 : AstraZeneca: Financial Performance, FY 2022-2023
  • Table 62 : AstraZeneca: Product Portfolio
  • Table 63 : AstraZeneca: Key/Recent Developments, 2021-2023
  • Table 64 : B. Braun SE: Company Snapshot
  • Table 65 : B. Braun SE: Financials, FY 2021-2022
  • Table 66 : B. Braun SE: Product Portfolio
  • Table 67 : B. Braun SE: News/Key Developments, 2023
  • Table 68 : BD: Company Snapshot
  • Table 69 : BD: Financial Performance, FY 2022-2023
  • Table 70 : BD: Product Portfolio
  • Table 71 : BD: News/Key Developments, 2021-2023
  • Table 72 : Cardinal Health: Company Snapshot
  • Table 73 : Cardinal Health: Financial Performance, FY 2022-2023
  • Table 74 : Cardinal Health: Product Portfolio
  • Table 75 : Cardinal Health: News/Key Developments, 2021-2023
  • Table 76 : Debiotech SA: Company Snapshot
  • Table 77 : Debiotech SA: Product Portfolio
  • Table 78 : Debiotech SA: News/Key Developments, 2022-2023
  • Table 79 : Diabeloop SA: Company Snapshot
  • Table 80 : Diabeloop SA: Product Portfolio
  • Table 81 : Diabeloop SA: News/Key Developments, 2021-2023
  • Table 82 : Emperra GmbH E-Health Technologies: Company Snapshot
  • Table 83 : Emperra GmbH E-Health Technologies: Product Portfolio
  • Table 84 : Emperra GmbH E-Health Technologies: News/Key Developments, 2022
  • Table 85 : Embecta Corp.: Company Snapshot
  • Table 86 : Embecta Corp.: Financial Performance, FY 2022-2023
  • Table 87 : Embecta Corp.: Product Portfolio
  • Table 88 : Embecta Corp.: News/Key Developments, 2021-2023
  • Table 89 : F. Hoffmann-La Roche Ltd.: Company Snapshot
  • Table 90 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022-2023
  • Table 91 : F. Hoffmann-La Roche Ltd.: Product Portfolio
  • Table 92 : Insulet Corp.: Company Snapshot
  • Table 93 : Insulet Corp.: Financial Performance, FY 2022-2023
  • Table 94 : Insulet Corp.: Product Portfolio
  • Table 95 : Insulet Corp.: News/Key Developments, 2023
  • Table 96 : Johnson & Johnson Services Inc.: Company Snapshot
  • Table 97 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022-2023
  • Table 98 : Johnson & Johnson Services Inc.: Product Portfolio
  • Table 99 : Johnson & Johnson Services Inc.: News/Key Developments, 2021-2023
  • Table 100 : LifeScan IP Holdings LLC.: Company Snapshot
  • Table 101 : LifeScan IP Holdings LLC.: Product Portfolio
  • Table 102 : LifeScan IP Holdings LLC.: News/Key Developments, 2021
  • Table 103 : Lilly: Company Snapshot
  • Table 104 : Lilly: Financial Performance, FY 2022-2023
  • Table 105 : Lilly: Product Portfolio
  • Table 106 : Lilly: Recent Developments, 2021-2022
  • Table 107 : Medtronic: Company Snapshot
  • Table 108 : Medtronic: Financial Performance, FY 2022-2023
  • Table 109 : Medtronic: Product Portfolio
  • Table 110 : Medtronic: News/Key Developments, 2021-2023
  • Table 111 : Novo Nordisk A/S: Company Snapshot
  • Table 112 : Novo Nordisk A/S: Financial Performance, FY 2022-2023
  • Table 113 : Novo Nordisk A/S: Product Portfolio
  • Table 114 : Novo Nordisk A/S: Recent Developments, 2021-2023
  • Table 115 : NuGen Medical Devices: Company Snapshot
  • Table 116 : NuGen Medical Devices: Financial Performance, FY 2021-2022
  • Table 117 : NuGen Medical Devices: Product Portfolio
  • Table 118 : NuGen Medical Devices: News/Key Developments, 2022
  • Table 119 : Owen Mumford Ltd.: Company Snapshot
  • Table 120 : Owen Mumford Ltd.: Product Portfolio
  • Table 121 : Sanofi: Company Snapshot
  • Table 122 : Sanofi: Financial Performance, FY 2022-2023
  • Table 123 : Sanofi: Product Portfolio
  • Table 124 : Sanofi: Recent Developments, 2022-2023
  • Table 125 : Sooil Developments Co. Ltd.: Company Snapshot
  • Table 126 : Sooil Developments Co. Ltd.: Product Portfolio
  • Table 127 : Tandem Diabetes Care Inc.: Company Snapshot
  • Table 128 : Tandem Diabetes Care Inc.: Financial Performance, FY 2022-2023
  • Table 129 : Tandem Diabetes Care Inc.: Product Portfolio
  • Table 130 : Tandem Diabetes Care Inc.: News/Key Developments, 2023-2024
  • Table 131 : Terumo Corp.: Company Snapshot
  • Table 132 : Terumo Corp.: Financial Performance, FY 2021-2022
  • Table 133 : Terumo Corp.: Product Portfolio
  • Table 134 : Terumo Corp.: News/Key Developments, 2022
  • Table 135 : Ypsomed AG: Company Snapshot
  • Table 136 : Ypsomed AG: Financial Performance, FY 2021-2022
  • Table 137 : Ypsomed AG: Product Portfolio
  • Table 138 : Ypsomed AG: News/Key Developments, 2022-2023
  • Table 139 : Government Regulatory Agencies and Professional Organizations

List of Figures

  • Summary Figure : Global Market for Emerging Insulin Drug Delivery Devices, by Type, 2020-2028
  • Figure 1 : Market Dynamics for Emerging Insulin Drug and Delivery Technologies
  • Figure 2 : Snapshot of the Worldwide Incidence of Diabetes, 2019-2045
  • Figure 3 : AstraZeneca: Revenue Share, by Segment, 2023
  • Figure 4 : AstraZeneca: Revenue Share, by Region/Country, 2023
  • Figure 5 : B. Braun SE: Revenue Share, by Business Unit, FY 2022
  • Figure 6 : B. Braun SE: Revenue Share, by Region/Country, FY 2022
  • Figure 7 : BD: Revenue Share, by Business Unit, FY 2023
  • Figure 8 : BD: Revenue Share, by Region/Country, FY 2023
  • Figure 9 : Cardinal Health: Revenue Share, by Business Unit, FY 2023
  • Figure 10 : Cardinal Health: Revenue Share, by Region/Country, FY 2023
  • Figure 11 : Embecta Corp.: Revenue Share, by Region/Country, FY 2023
  • Figure 12 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
  • Figure 13 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Region/Country, FY 2023
  • Figure 14 : Insulet Corp.: Revenue Share, by Business Unit, FY 2023
  • Figure 15 : Insulet Corp.: Revenue Share, by Region/Country, FY 2023
  • Figure 16 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2023
  • Figure 17 : Johnson & Johnson Services Inc.: Revenue Share, by Region/Country, FY 2023
  • Figure 18 : Lilly: Revenue Share, by Product Type, FY 2023
  • Figure 19 : Lilly: Revenue Share, by Region/Country, FY 2023
  • Figure 20 : Medtronic: Revenue Share, by Business Unit, FY 2023
  • Figure 21 : Medtronic: Revenue Share, by Region/Country, FY 2023
  • Figure 22 : Novo Nordisk A/S: Revenue Share, by Business Unit, FY 2023
  • Figure 23 : Novo Nordisk A/S: Revenue Share, by Region/Country, FY 2023
  • Figure 24 : NuGen Medical Devices: Revenue Share, by Region, FY 2022
  • Figure 25 : Sanofi: Revenue Share, by Business Segment, FY 2023
  • Figure 26 : Sanofi: Revenue Share, by Region, 2023
  • Figure 27 : Tandem Diabetes Care Inc.: Revenue Share, by Region/Country, FY 2023
  • Figure 28 : Terumo Corp.: Revenue Share, by Business Unit, FY 2022
  • Figure 29 : Terumo Corp.: Revenue Share, by Region/Country, FY 2022
  • Figure 30 : Ypsomed AG: Revenue Share, by Business Unit, FY 2022
  • Figure 31 : Ypsomed AG: Revenue Share, by Region/Country, FY 2022
目次
Product Code: HLC156B

The global market for emerging insulin drug delivery devices is expected to grow from $55.8 billion in 2023 and projected to reach $88.9 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.8% from 2023 through 2028.

The global market for insulin syringes and vials is expected to grow from $24.3 billion in 2023 and projected to reach $37.0 billion by the end of 2028, at a CAGR of 8.7% from 2023 through 2028.

The global market for smart insulin pens is expected to grow from $4.2 billion in 2023 and projected to reach $7.7 billion by the end of 2028, at a CAGR of 12.6% from 2023 through 2028.

Report Scope:

This report discusses the implications of the growing diabetes epidemic on the global and regional markets for emerging insulin drug and delivery technologies. It discusses companies in the relevant pharmaceutical and medical industries and provides profiles of the leading players as well as an update on M&A activity. The report's patent analysis focuses on developments in Japan, Europe and the U.S. Five-year global sales forecasts are provided for the major categories of insulin drug and delivery technologies and devices categories.

This report segments the global market into four regions -

  • North America.
  • Europe.
  • Asia-Pacific.
  • Rest of the World (RoW).

Report Includes:

  • 57 data tables and 83 additional tables
  • An overview and industry analysis of the global markets for emerging insulin drug and delivery technologies, with an emphasis on plastic insulin syringes and vials
  • Analyses of the global market trends, with historical market revenue data (sales figures) for 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
  • Estimate of the actual market size and revenue growth forecast, and a corresponding market share analysis by product type, application and region
  • A look at the emerging technologies that have potential in the diabetes market, with improved glucose control, along with improved delivery methods
  • Examination of the current state of the insulin drug and delivery industry structure, focusing on technological updates and issues surrounding insulin pens and insulin syringes, ongoing research activities, and regulatory and pricing scenarios
  • Discussion of market dynamics, clinical trial applications, regulations, and penetration of technologies in the pharmaceutical and biotechnology markets
  • Discussion of the ESG developments and how they impact corporate performance, ratings and matrices and consumer attitude, as well as the ESG practices of leading pharma and biotech companies
  • Review of the key patent grants/publications for insulin as a drug, along with its delivery methods
  • Analysis of the competitive landscape based on recent developments and segmental revenues of leading companies
  • Profiles of the leading market players

Table of Contents

Chapter 1 Introduction

  • Overview
  • Study Goals and Objectives
  • Reasons for Doing the Study
  • What's New in this Report?
  • Scope of Report
  • Information Sources
  • Methodology
  • Secondary Research
  • Geographic Breakdown
  • Segmentation Breakdown

Chapter 2 Summary and Highlights

  • Market Outlook
  • Market Summary
  • Developments and Trends

Chapter 3 Market Overview

  • Introduction
  • What is Diabetes?
  • Types of Diabetes
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes Mellitus or Hyperglycemia in Pregnancy
  • Impaired Glucose Tolerance and Impaired Fasting Glucose
  • Epidemiology of Diabetes
  • Gender Distribution
  • Regional Disparities
  • Market Dynamics Snapshot
  • Factors Affecting the Market
  • Market Drivers
  • Market Restraints

Chapter 4 Global Market for Emerging Insulin Drug and Delivery Technologies, by Type

  • Overview
  • Technological Advances in Insulin Syringes
  • Insulin Delivery Pen Devices
  • Disposable Insulin Pens
  • Reusable Insulin Pens
  • Technological Advances in Insulin Drug and Delivery Pen Devices
  • External Insulin Pumps
  • Technological Advances in Insulin Pump Systems
  • Implantable Insulin Pumps
  • Closed-Loop Artificial Pancreas
  • Bionic Pancreas
  • Smart Pens

Chapter 5 Global Market for Emerging Insulin Drug Delivery Devices, by Application

  • Overview
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes

Chapter 6 Global Market for for Insulin Drug Delivery Devices, by Region

  • Overview
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 7 Regulatory Landscape

  • Overview
  • U.S. Regulations for Insulin Drug and Delivery Technologies
  • European Regulations for Insulin Drug and Delivery Technologies
  • Japan's Regulations for Insulin Drug and Delivery Technologies
  • China's Regulations for Insulin Drug and Delivery Technologies

Chapter 8 Sustainability in the Insulin Drug and Delivery Market: An ESG Perspective

  • Introduction
  • ESG Performance Analysis

Chapter 9 Emerging Technologies

  • Introduction
  • Patient Outcomes Beyond Glucose Control

Chapter 10 Patent Analysis

  • Overview

Chapter 11 M&A and Venture Funding Outlook

  • M&A Analysis

Chapter 12 Competitive Landscape

  • Overview

Chapter 13 Company Profiles

  • ASTRAZENECA
  • B. BRAUN SE
  • BD
  • CARDINAL HEALTH
  • DEBIOTECH SA
  • DIABELOOP SA
  • EMPERRA GMBH E-HEALTH TECHNOLOGIES
  • EMBECTA CORP.
  • F. HOFFMANN-LA ROCHE LTD.
  • INSULET CORP.
  • JOHNSON & JOHNSON SERVICES INC.
  • LIFESCAN IP HOLDINGS LLC.
  • LILLY
  • MEDTRONIC
  • NOVO NORDISK A/S
  • NUGEN MEDICAL DEVICES
  • OWEN MUMFORD LTD.
  • SANOFI
  • SOOIL DEVELOPMENTS CO. LTD.
  • TANDEM DIABETES CARE INC.
  • TERUMO CORP.
  • YPSOMED AG

Chapter 14 Appendix

  • Government Regulatory Agencies and Professional Organizations
  • List of References